• Home
• Corp. Overview
• Org. & Mgmt.
• Technology
• product pipeline
  • BP-100-1.01
  • BP-100-1.02
  • BP-100-2.01
• SEC filings
• News

Product Pipeline

 

 

NEWS

January 4, 202	Bio-Path Holdings to Present at Biotech Showcase 2012 Conference
December 13, 2011	Bio-Path Holdings' Initial Phase I Data in Leukemia Clinical Trial Demonstrates that Its Neutral Lipid Delivery Technology Antisense Drug BP-101-100-1.01 (Liposomal Grb-2) Is Well Tolerated with Activity Seen at Low-Starting Dose
November 15, 2011	Press Release Form 8-K - 3rd Quarter Financial Results
October 24, 2011	Proxy Statement fothereer 2011
October 19, 2011	Bio-Path Holdings to Present at the 10th Annual BIO Investors Forum Conference in San Francisco on Wednesday, October 26, 2011. Link to Conference at 3:00pm Pacific Time
October 4, 2011	Initial Data from Bio-Path Holdings' Phase I Clinical Trial Accepted for Presentation at American Society of Hematology Annual Meeting
September 6, 2011	Bio-Path Holdings to Present at the Rodman & Renshaw Annual Global Investment Conference Link to Conference on September 13, 2011 at 4:55 pm Eastern Time
August 11, 2011	First Cohort Successfully Completed in Bio-Path Holding’s Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
July 27, 2011	Bio-Path recently featured in Genomeweb/Gene Silencing News
May 17, 2011	Bio-Path Holdings Reports First Quarter 2011 Financial Results
April 28, 2011	Bio-Path Holdings Appoints Dr. Ana M. Tari Director, Preclinical Operations and Research
April 4, 2011	Zack's Small-Cap Research Release
March 31, 2011	Bio-Path Holdings Reports Fiscal Year 2010 Operation and Financial Results
February 23, 2011	CEOCFO Interviews Peter H. Nielsen, CEO
February 23, 2011	Zack's Small-Cap Research Release
November 15, 2010	Bio-Path Holdings Reports Third Quarter 2010 Financial Results
November 3, 2010	Bio-Path Holdings Awarded Grant From The U.S. Government's Qualifying Therapeutic Discovery Project Program
August 17, 2010	Bio-Path Holdings Reports Fiscal 2010 Second Quarter Financial Results Company Also Completes Initial Sale of Registered Shares Under Financing With Lincoln Park Capital
July 29, 2010	Bio-Path Holdings announces Dosing of First Patient in a Phase I Clinical Trial of its Liposomal Grb-2 Cancer Drug Candidate
June 4, 2010	Bio-Path Holdings Signs Equity Financing Deal Equity Purchase Agreement With Institutional Investor Lincoln Park Capital to Provide Up to $7 Million In New Capital
March 12, 2010	FDA Allows IND For Bio-Path Holdings' Liposomal Grb-2 Company to Commence Phase I Clinical Trial Of Its Cancer Drug To Treat CML, AML, ALL, & MDS
December 14, 2009	Bio-Path Holdings, Inc. Completes Private Placement Capital Raise and Provides Update to IND Status
November 2, 2009	Bio-Path Holdings, Inc. Operations Update
September 22, 2009	Bio-Path Holdings, Inc. Announces Plans To Develop Liposome Tumor Targeting Technology Licensed from The University of Texas M. D. Anderson Cancer Center
June 23, 2009	Bio-Path Holdings, Inc. Provides Operations Update and Overview Of New Targeting Technology
June 6, 2009	Proxy Statement and Proxy
April 14, 2009	Bio-Path Holdings, Inc. Announces Clinical Support Agreement With ACORN And Names Bradley G. Somer, M.D., As Medical Officer For Phase I Clinical Trial
December 10, 2008	Letter To Shareholders
December 3, 2008	Bio-Path Holdings, Inc. Retains Alliance Advisors, LLC to Implement Investor Relations Program
November 17, 2008	Bio-Path Holdings, Inc. Announces the Signing of a Drug Manufacturing Agreement with Althea Technologies, Inc.
June 23, 2008	Bio-Path Holdings Announces Dr. Hans A. de Hann Has Joined The Company As Medical Director
March 3, 2008	Bio-Path Becomes a Publicly Traded Company

 

 

 

 

 

Copyright 2008, Bio-Path Holdings, Inc., All rights reserved.